Development of CNS Penetrant Inhibitors of Toxoplasma Gondii Cathepsin L
Year: 2018
Type: article
Abstract: Toxoplasma gondii chronically infects ~2 billion people worldwide. This neurotropic protozoan is the 2nd leading cause of death due to foodborne illness in the US, and has been designated as one of five Neglected Parasitic Infections targeted by the CDC for public health action. Currently, there is no efficacious T. gondii therapeutic capable of treating the chronic dormant-phase toxoplasmosis infection in the CNS. T. gondii cathepsin L (TgCPL) has been implicated as a viable target for treatment of the chronic stage infection. Confirmation that TgCPL inhibition can eliminate neuronal cysts in a mouse with chronic toxoplasmosis is a crucial step in demonstrating that TgCPL is a valid target in chronic toxoplasmosis. Initially, a series of TgCPL dipeptide nitrile inhibitors was developed, improving potency for the T. gondii enzyme from 2 µM to as low as 115 nM. Although we successfully demonstrated that this compound class can penetrate the blood brain barrier, it also exhibits rapid clearance in vivo. A high throughput screen was then conducted and a triazine nitrile scaffold was selected based on literature precedent of this chemotype as inhibitors of human cathepsins and predicted BBB penetrant properties. Scaffold hopping to this chemotype resulted in an instantaneous gain of potency (TgCPL IC50 = 34 nM), however reduced metabolic stability relative to the corresponding dipeptide. Analogs were then synthesized to optimize metabolic stability, CNS permeability, and selectivity over human isoforms. Overall, we improved potency against TgCPL to as low as 5 nM and identified features that can be exploited to gain selectivity vs HsCPL (10-fold), and significantly improved metabolic stability (up to t1/2 >60 min in MLM). Importantly, we achieved CNS penetrance (up to Brain /Plasma = 1.4) and demonstrated that treatment of chronic stage T. gondii bradyzoite cysts with triazine nitrile inhibitors reduces parasite viability with efficacy equivalent to a TgCPL genetic knockout. This is the first example of a CNS penetrant, reversible TgCPL inhibitor showing efficacy in an in vitro model of the chronic stage parasite. Current endeavors are advancing toward in vivo proof-of-concept that pharmacological inhibition of TgCPL is an effective method of treating chronic T. gondii infection in the CNS.
Author: Jeffery D. Zwicker
Language: English
Subfield: Parasitology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W3146337382
